Patents matching “hydrogen”

US 9018216

Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof

Vertex Pharmaceuticals Incorporated · Granted Apr 28, 2015 · Expires Apr 23, 2035

PT 2303855

CATALYTIC PROCESS FOR ASYMMETRIC HYDROGENATION

BIAL PORTELA & Cª S A [PT] · Granted Mar 11, 2015 · Expires Mar 6, 2035

US 8927730

Intramolecular hydrogen-bonded nitric oxide synthase inhibitors

Northwestern University · Granted Jan 6, 2015 · Expires Jan 1, 2035

US 8883438

Method for diagnosing cell proliferation disorders having a neoactive mutation at residue 97 of isocitrate dehydrogenase 1

Agios Pharmaceuticals, Inc. · Granted Nov 11, 2014 · Expires Nov 6, 2034

US 8802733

Aldehyde dehydrogenase inhibitors as novel depigmenting agents

The Board of Regents of the University of Texas System · Granted Aug 12, 2014 · Expires Aug 7, 2034

US 8481599

Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism

TONIX PHARMACEUTICALS HOLDING CORP · Granted Jul 9, 2013 · Expires Jul 4, 2033

US 8114900

Amorphous carvedilol dihydrogen phosphate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Feb 14, 2012 · Expires Feb 9, 2032

US 8092838

Use of hydrogen sulfide in the treatment of eye diseases

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Jan 10, 2012 · Expires Jan 5, 2032

US 7998992

Oxazolidinone derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1

Institute of Medicinal Molecular Design, Inc. · Granted Aug 16, 2011 · Expires Aug 11, 2031

US 7759339

Hydroxysteroid dehydrogenase inhibitors

Takeda San Diego, Inc. · Granted Jul 20, 2010 · Expires Jul 15, 2030

US 7527952

Crystals of inosine monophosphate dehydrogenase/oxidized inosine monophosphate thiomidate intermediate/mycophenolic acid (IIMPDH/XMP*/MPA)

Vertex Pharmaceuticals Incorporated · Granted May 5, 2009 · Expires Apr 30, 2029

US 7276629

Hydrogenation of imine intermediates of sertraline with catalysts

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 2, 2007 · Expires Sep 27, 2027

US 6375946

Enhanced activation of natural killer cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor

Maxim Pharmaceuticals, Inc. · Granted Apr 23, 2002 · Expires Apr 18, 2022

US 6328959

Intestinal hydrogen removal using hydrogen-metabolizing microbes

United States of America as represented by the Secretary of the Air Force · Granted Dec 11, 2001 · Expires Dec 6, 2021

US 6245563

Enhanced activation of natural killer cells using an NK cell activator and hydrogen peroxide scavenger or inhibitor

Maxim Pharmaceuticals, Inc. · Granted Jun 12, 2001 · Expires Jun 7, 2021

US 6071509

Enhanced activation of natural killer cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor

Maxim Pharmaceuticals, Inc. · Granted Jun 6, 2000 · Expires Jun 1, 2020

US 6063373

Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor

Maxim Pharmaceuticals, Inc. · Granted May 16, 2000 · Expires May 11, 2020